<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------------------
FORM 8-K/A
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
August 15, 2000
------------------------------------
Date of Report (Date of
earliest event reported)
CORIXA CORPORATION
-------------------------------------------------------------------------------
(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)
<TABLE>
<S> <C> <C>
DELAWARE 0-22891 91-1654387
----------------------------- --------------------------- ---------------------------
(State or Other Jurisdiction (Commission File No.) (IRS Employer
of Incorporation) Identification No.)
</TABLE>
1124 COLUMBIA STREET, SUITE 200, SEATTLE, WASHINGTON 98104
-------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(206) 754-5711
-------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
NONE
-------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE> 2
EXPLANATORY NOTE
This Amendment on Form 8-K/A to the Current Report on Form 8-K of Corixa
Corporation, filed on August 28, 2000, amends the exhibits detailed in Item 5
"Other Events" and the exhibits listed under Item 7(c) "Financial Statements,
Pro Forma Financial Information and Exhibits."
ITEM 5. OTHER EVENTS
On August 15, 2000, Corixa Corporation announced that it had entered
into a multi-year development, commercialization and license agreement with
Medicis Pharmaceutical Corporation covering Corixa's psoriasis immunotherapeutic
product, PVAC(TM) treatment. Further details regarding this announcement are
contained in Corixa's press release dated August 15, 2000, which is attached to
this report as exhibit 99.1. A copy of the Development, Commercialization and
License Agreement between Corixa and Medicis dated August 15, 2000 is attached
to this report as exhibit 10.1.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(c) Exhibits
10.1* Development, Commercialization and License Agreement between
Corixa Corporation and Medicis Pharmaceutical Corporation dated
August 15, 2000
99.1 Corixa Corporation Press Release dated August 15, 2000
----------
* Confidential treatment requested.
<PAGE> 3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CORIXA CORPORATION
By: /s/ Steven Gillis
----------------------------------------
Name: Steven Gillis
Dated: October 30, 2000 Its: Chief Executive Officer
<PAGE> 4
EXHIBIT INDEX
Exhibit Number Description
10.1* Development, Commercialization and License Agreement
between Corixa Corporation and Medicis Pharmaceutical
Corporation dated August 15, 2000
99.1 Corixa Corporation Press Release dated August 15, 2000
----------
* Confidential treatment requested.
